Compounds > 3-deazaneplanocin
Page last updated: 2024-08-25

3-deazaneplanocin and Leukemia, Myeloid, Acute

3-deazaneplanocin has been researched along with Leukemia, Myeloid, Acute in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19901 (20.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's2 (40.00)24.3611
2020's1 (20.00)2.80

Authors

AuthorsStudies
Feng, Y; Gu, J; He, Y; Huang, K; Kang, B; Li, X; Li, Y; Liu, J; Long, B; Mai, Y; Pan, G; Shan, Y; Sun, Y; Wang, T; Wen, R; Zhang, C; Zhang, T; Zhang, W; Zhang, X; Zhu, Y1
Averink, TV; Brumatti, G; Ekert, PG; Holik, AZ; Infusini, G; Sandow, JJ; Webb, AI1
Atadja, P; Balusu, R; Bhalla, KN; Buckley, KM; Chen, J; Fernandez, P; Fiskus, W; Jillella, A; Koul, S; Marquez, VE; Rao, R; Shi, H; Sreekumar, A; Ustun, C; Wang, Y1
Bi, C; Cheong, LL; Chng, WJ; Koh, TL; Liu, SC; Mahara, S; Tay, KG; Yu, Q; Zhou, J1
Chiang, PK; Glazer, RI; Hartman, KD; Knode, MC; Marquez, VE; Richard, MM; Tseng, CK1

Other Studies

5 other study(ies) available for 3-deazaneplanocin and Leukemia, Myeloid, Acute

ArticleYear
Vitamin C promotes anti-leukemia of DZNep in acute myeloid leukemia.
    Biochimica et biophysica acta. Molecular basis of disease, 2022, 05-01, Volume: 1868, Issue:5

    Topics: Adenosine; Ascorbic Acid; Enhancer of Zeste Homolog 2 Protein; Histone Methyltransferases; Humans; Leukemia, Myeloid, Acute

2022
Quantitative proteomic analysis of EZH2 inhibition in acute myeloid leukemia reveals the targets and pathways that precede the induction of cell death.
    Proteomics. Clinical applications, 2017, Volume: 11, Issue:9-10

    Topics: Adenosine; Animals; Carcinogenesis; Cell Death; Enhancer of Zeste Homolog 2 Protein; Gene Expression Regulation, Neoplastic; Leukemia, Myeloid, Acute; Mice; Molecular Targeted Therapy; Proteomics

2017
Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.
    Blood, 2009, Sep-24, Volume: 114, Issue:13

    Topics: Adenosine; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carrier Proteins; Cell Cycle; DNA-Binding Proteins; Drug Evaluation, Preclinical; Enhancer of Zeste Homolog 2 Protein; Enzyme Inhibitors; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Histone Methyltransferases; Histone-Lysine N-Methyltransferase; Histones; HL-60 Cells; Humans; Hydroxamic Acids; Indoles; Leukemia, Myeloid, Acute; Neoplasm Proteins; Nuclear Proteins; Panobinostat; Polycomb Repressive Complex 2; Transcription Factors; Treatment Outcome; Tumor Cells, Cultured

2009
The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML.
    Blood, 2011, Sep-08, Volume: 118, Issue:10

    Topics: Adenosine; Animals; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carrier Proteins; Cell Proliferation; Chromatin Immunoprecipitation; DNA-Binding Proteins; Enhancer of Zeste Homolog 2 Protein; Enzyme Inhibitors; Epigenomics; Female; Gene Expression Profiling; Gene Silencing; Histone Methyltransferases; Histone-Lysine N-Methyltransferase; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; Oligonucleotide Array Sequence Analysis; Polycomb Repressive Complex 2; Polycomb-Group Proteins; Reactive Oxygen Species; Repressor Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Transcription Factors; Tumor Cells, Cultured

2011
3-Deazaneplanocin: a new and potent inhibitor of S-adenosylhomocysteine hydrolase and its effects on human promyelocytic leukemia cell line HL-60.
    Biochemical and biophysical research communications, 1986, Mar-13, Volume: 135, Issue:2

    Topics: Adenosine; Adenosylhomocysteinase; Animals; Cell Division; Cell Line; Cell Survival; Cricetinae; Humans; Hydrolases; Leukemia, Myeloid, Acute; Liver

1986